臨床研究支援事業
成果一覧
CSPOR
乳癌
Lancet Oncol . 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial Masakazu Toi , Shigeru Imoto , Takanori Ishida , Yoshinori Ito , Hiroji Iwata , Norikazu Masuda , Hirofumi Mukai , Shigehira Saji , Akira Shimizu , Takafumi Ikeda , Hironori Haga , Toshiaki Saeki , Kenjiro Aogi , Tomoharu Sugie , Takayuki Ueno , Takayuki Kinoshita , Yuichiro Kai , Masahiro Kitada , Yasuyuki Sato , Kenjiro Jimbo , Nobuaki Sato , Hiroshi Ishiguro , Masahiro Takada , Yasuo Ohashi , Shinji Ohno
肺癌
Japanese Journal of Clinical Oncology, Volume 49, Issue 6, June 2019, Pages 554–558,
Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial) （臼井 一裕：NTT東日本関東病院）
大腸癌
腎癌
第54回日本癌治療学会学術集会 / 2016年10月
第104回日本泌尿器科学会総会 / 2016年4月23日
根治切除不能または転移性の腎細胞癌患者 に対する1st line TKI療法不応後の エベロリムスの有効性および安全性の検討 ― 多施設共同第Ⅱ相試験 ―（杉山貴之：浜松医科大学泌尿器科学講座）
CSP-A-TOP
J-05
J Bone Miner Metab ; 38, 412–417, 2020
Design of a randomized trial of teriparatide followed by alendronate:Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Tanaka S, Mori S, Hagino H, Sugimoto T
J-04
J Bone Miner Metab ; 37, 886–892, 2019
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M ,Adequate Treatment of Osteoporosis(A-TOP) research group.
J Bone Miner Metab ; First Online: 17 July 2018 Online ISSN 1435-5604 . DOI 10.1007/s00774-018-0942-z
Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Moei S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.
J-03
Osteoporos Int;28(6);1893-1901,2017,DOI 10,1007/S 00198-017-3966-7
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, for the A-TOP(Adequate Treatment of Osteoporosis) Research Group.
J Bone Miner Metab ;35(4);385-395,2017.DOI 10.1007/s00774-016-0768-5
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.
J Bone Miner Metab;32(3); 298-304, 2014
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki
J-02
Clin Therap;36(2);225-235, 2014
Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Z, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M for the Adequate Treatment of Osteoporosis.(A-TOP)research group.
J Bone Miner Metab;33(6): 642-650, 2015
Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan. Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.
Curr Med Res Opin;27(6);1273-84,2011
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis)research group
J Bone Miner Metab;29(1):37-43,2011
Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Hosoi T, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H et al.
A-01
Jpn J Pharmacoepidemiol;21(1);13-19,2016,DOI.org/10.3820/jjpe.21.13
Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information. Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.
CSP-LD
LD-16
Journal of Bone and Mineral Metabolism volume 38, pages230–239(2020)
Journal of Clinical Trials:2017, 7:6 DOI: 10.4172/2167-0870.1000336
LD-15
American Journal of Kidney Diseases :August 31, 2018
LD-12
Circulation Journal: 2015 Volume 79 Issue 5 Pages 981-990
LD-11
Heart and Vessels volume 30, pages805–817(2015)
LD-10
Digestive Diseases and Sciences volume 63, pages1910–1919(2018)
LD-09
International heart journal／2018 Volume 59 Issue 2 Pages 315-320
American Heart Association(AHA)_ Late breaking/ 2017年11月13日
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Takeshi Kimura, Teruo Inoue, Isao Taguchi, Hiroshi Iwata, Satoshi Iimuro, Takafumi Hiro, Yoshihisa Nakagawa, Yukio Ozaki, Yasuo Ohashi, Hiroyuki Daida, Hiroaki Shimokawa, Ryozo Nagai, on behalf of the REAL-CAD Study Investigators
LD-08
American Heart Association（AHA）_Late breaking/2018年11月10日
Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-Cholesterol.
Yasuyoshi Ouchi , Hidenori Arai, Jun Sasaki, Koutaro Yokote, Masanari Kuwabara, Kazumasa Harada, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Hideki Ito on behalf of the EWTOPIA investigators
LD-07
Journal of Atheroscler Thromb. 2017 Jan 1; 24(1): 77–94.doi: 10.5551/jat.35626
疫学調査
Kidney International (2017) 91, 227–234
Clinical and Experimental Nephrology volume 21, pages446–456(2017)
疫学調査
Annals of Vascular Diseases／ 2019 Jun 25; 12(2): 182–186.
疫学調査
日本糖尿病学会・2009年5月
米国糖尿病学会 ニューオリンズ・2009年6月
CSP-HOR
CSP-CCR
C-10
第66回日本産科婦人科学会学術講演会/2014
C-09
日本性感染症学会誌 2013; 24(1): 103-9/2013
尖圭コンジローマ患者のQOL調査：多施設共同研究 (J-HERS Study)・入江, et al.
第65回 日本産科婦人科学会学術講演会/2013
尖圭コンジローマに罹患した日本人女性のQuolity of Life (QOL) 調査: 多施設共同研究 (J-HERS Study)・伊藤富士子
第25回 日本性感染症学会学術大会/2012
尖圭コンジローマ患者のQOL調査・入江琢也
28th International Papillomavirus Conference (IPV)/2012
Multi-Center Study (J-HERS) for Quality of Life of Women with Genital Warts in Japan -Interim Report-・F Ito
C-08
第52回 日本臨床細胞学会 秋季大会/2013
日本における高リスク型HPVを再考する・伊藤富士子
第54回 日本臨床細胞学会総会 春季大会/2013
子宮頚部細胞診とHPV感染および型別診断の大規模研究：J-HERS多施設共同研究・前濱俊之
第54回 日本臨床細胞学会総会 春季大会/2013
子宮頚部液状細胞診とHPV-DNA検査併用の意義：J-HERS大規模調査・笹川寿之
第65回 日本産科婦人科学会学術講演会/2013
日本人女性の子宮頚部に感染するHPV型と細胞診談の大規模研究：多施設共同研究 (J-HERS Study）・前濱俊之
第25回 日本性感染症学会学術大会/2012
HPV DNA型調査・前濱俊之
28th International Papillomavirus Conference (IPV)/2012
A multii-center study (J-HERS) for prevalent HPV genotypes and abnormal cytology in young Japanese women・T Sasagawa
C-06
27th International Papillomavirus Conference (IPV)/2011
Estimation of the incidence of genital wart, cervical intraepithelial neoplasia and cervical cancer in Japan (J-HERS)・T Sasagawa
C-05
日本呼吸器学会/2014
呼吸器疾患未治療の日本人COPD患者に対するガイドライン薬物治療効果の検討・瀬戸口靖弘（東京医科大学病院）
その他
日本臨床試験学会 第8回学術集会総会 IN 大阪
メイキング・ チェックリスト ～臨床研究への挑戦 ～
○浅野 昌彦 、荒井 秀和、齋藤 由紀、寺本 藍、 長尾 典明、村田 翔、吉田 和史、西谷 政昭
第15回 CRCと臨床試験の在り方を考える会議 2015 in KOBE
医師主導臨床研究の試験運営における財団の果たす役割～臨床研究のパイオニアとしての挑戦
○井ノ上仁子、中里淳子、秋田美穂、浅野昌彦、西村尚子、西谷政昭、宮崎輝彦